Today GSK China announces a strategic private-public partnership with the National Health...

Today GSK China announces a strategic private-public partnership with the National Health...

Today GSK China announces a strategic private-public partnership with the National Health and Family Planning Commission (NHFPC) to help build a grassroots COPD expert network in counties across China.

Over the next 5 years, the “COPD Prevention and Treatment Education and Health Promotion Project” aims to provide training to 6,000 primary healthcare doctors across the country on the early screening and treatment of COPD. The project will be managed by the People’s Medical Publishing House and supported by GSK through an unrestricted grant.

This project is part of a strategic public health commitment by GSK China to China centering on primary care. A similar partnership with the Development Center for Medical Science and Technology of NHFPC will involve the training of grassroots doctors in the diagnosis and treatment of Hepatitis B.

Over 13,000 doctors are planned to undergo this training over the next three to five years through these programmes.

Herve Gisserot, Senior VP GSK China commented: “GSK is committed to supporting the Chinese government’s Healthcare Reform agenda. Building capability in the area of primary care is crucial as the country establishes a medical classification system to drive patient flow away from overcrowded large public hospitals. COPD is a chronic disease that, if not treated early, will result in major health consequences for patients, and eventually a burden to the healthcare system.”